Metabolically Healthy Obesity
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities, mainly in those individuals who develop cardiovascular diseases, type 2 diabetes, osteoarthritis, and cancer. However, there is a large variation in the individual risk to developing obesity-associated comorbid diseases that cannot simply be explained by the extent of adiposity. Observations that a proportion of individuals with obesity have a significantly lower risk for cardiometabolic abnormalities led to the concept of metabolically healthy obesity (MHO). Although there is no clear definition, normal glucose and lipid metabolism parameters—in addition to the absence of hypertension—usually serve as criteria to diagnose MHO. Biological mechanisms underlying MHO lower amounts of ectopic fat (visceral and liver), and higher leg fat deposition, expandability of subcutaneous adipose tissue, preserved insulin sensitivity, and beta-cell function as well as better cardiorespiratory fitness compared to unhealthy obesity. Whereas the absence of metabolic abnormalities may reduce the risk of type 2 diabetes and cardiovascular diseases in metabolically healthy individuals compared to unhealthy individuals with obesity, it is still higher in comparison with healthy lean individuals. In addition, MHO seems to be a transient phenotype further justifying therapeutic weight loss attempts—even in this subgroup—which might not benefit from reducing body weight to the same extent as patients with unhealthy obesity. Metabolically healthy obesity represents a model to study mechanisms linking obesity to cardiometabolic complications. Metabolically healthy obesity should not be considered a safe condition, which does not require obesity treatment, but may guide decision-making for a personalized and risk-stratified obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hyperplasia, referring to an increase in the number of adipocytes, is associated with an increase in subcutaneous fat volume and protective signals, and is associated with MHO (50).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“On the contrary, hypertrophic adipocytes, in which existing adipocytes enlarge, is associated with increased dysfunction and MUHO (50), which contributes to IR and subsequent T2D (52, 53).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 7×
“8 Endocrine Reviews, June 2020, 41(3):1–16 Blüher Metabolically Healthy Obesity sex hormones may play a role in the transition from MHO to MUO.”
BackgroundInfluentialSelf-citationThe global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Cited by
Items 201–300 of 999
Immune Cell Regulation of White Adipose Progenitor Cell Fate
Altun, İ., Yan, X.-D., & Ussar, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.859044 · Cited by 14
Ooi, D. S. Q., Toh, J. Y., Ng, L. Y. B., Peng, Z., Yang, S., Rashid, N. S. B. S. A., Sng, A. A., Chan, Y. H., Chong, M. F., & Lee, Y. S. (2022) · Nutrients · doi:10.3390/nu14224796 · Cited by 21
Guerrero‐Romero, F., Castellanos-Juárez, F. X., Salas-Pacheco, J. M., Morales-Gurrola, F. G., Salas-Leal, A. C., & Simental‐Mendía, L. E. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08338-z · Cited by 20
Himbert, C., Ose, J., Gigic, B., Viskochil, R. H., Santuci, K., Lin, T., Ashworth, A., Cohan, J. N., Scaife, C. L., Jedrzkiewicz, J., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10695-8 · Cited by 21
“Physical activity may counteract the obesity-associated metabolic phenotype including systemic inflammation and insulin resistance, also referred to as ‘metabolically healthy obesity’ [12, 13].”
BackgroundFat as a Friend or Foe of the Bone
Gruneisen, E., Kremer, R. B., & Duque, G. (2024) · Current Osteoporosis Reports · doi:10.1007/s11914-024-00864-4 · Cited by 24
“MUHO might be the consequence of an impaired adipose tissue function after a chronic positive energy balance, leading to the inability of the subcutaneous adipose tissue to expand sufficiently to counter this long-term imbalance [7].”
Pan, R., Wang, R., Zhang, Y., Ji, H., Liang, X. Y., & Zhao, Y. (2024) · Bone · doi:10.1016/j.bone.2024.117134 · Cited by 23
Novel antiadipogenic effect of menadione in 3T3-L1 cells
Funk, M. I., Conde, M. A., Piwien‐Pilipuk, G., & Uranga, R. M. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109491 · Cited by 20
Myocardial Geometry and Dysfunction in Morbidly Obese Adolescents (BMI 35–40 kg/m2)
Siurana, J. M., Ventura, P. S., Yeste, D., Riaza, L., Arciniegas, L., Clemente, M., Torres, M., Amigó, N., Giralt, G., Rosés‐Noguer, F., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.07.026 · Cited by 20
Shao, F., Chen, Y., Xu, H., Chen, X., Zhou, J., Wu, Y., Tang, Y., Wang, Z., Zhang, R., Lange, T., et al. (2022) · Nutrients · doi:10.3390/nu14163370 · Cited by 20
Cai, S., Dang, J., Zhong, P., Ma, N., Liu, Y., Shi, D., Zou, Z., Dong, Y., Ma, J., & Song, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.980332 · Cited by 19
Is the Biphasic Effect of Diabetes and Obesity on Fetal Growth a Risk Factor for Childhood Obesity?
van Poppel, M. N. M., Damm, P., Mathiesen, E. R., Ringholm, L., Zhang, C., & Desoyé, G. (2023) · Diabetes Care · doi:10.2337/dc22-2409 · Cited by 19
Insights into the role of RNA m6A modification in the metabolic process and related diseases
Hu, H., Li, Z., Xie, X., Liao, Q., Hu, Y., Gong, C., Gao, N., Yang, H., Xiao, Y., & Chen, Y. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.04.038 · Cited by 20
The melanocortin‐4 receptor pathway and the emergence of precision medicine in obesity management
Fansa, S., & Acosta, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15555 · Cited by 19
“28 MHO should not be viewed as a safe condition; it should instead be used as a guide in obesity management, to provide a more personalized and risk-stratified treatment, thus aligning with the philosophy of precision medicine for obesity.”
BackgroundGuan, H., Zhao, S., Li, J., Wang, Y., Niu, P., Zhang, Y., Zhang, Y., Fang, X., Miao, R., & Tian, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1363877 · Cited by 21
Reverse epidemiology of obesity paradox: Fact or fiction?
Kishore, B. K. (2024) · Physiological Reports · doi:10.14814/phy2.70107 · Cited by 23
“Over a five-year period (2015–2020), there was a 17.8% increase in LD in adults as compared to 2.1% increase in diabetes among people with overweight FIGURE 6 Remodeling of white and brown adipose tissues by exercise in subjects with diet-induced obesity.”
BackgroundInfluentialZhou, Q., Fu, Z., Gong, Y., Seshachalam, V. P., Li, J., Ma, Y., Liang, H., Guan, W., Lin, S., Ghosh, S., et al. (2020) · Obesity · doi:10.1002/oby.22950 · Cited by 18
“Second, MUO may have more severe immune cell infiltration, which was supported by earlier studies in different cohorts (37-39).”
ResultThe new kids on the block: Emerging obesogens
Chamorro-García, R., & Veiga‐Lopez, A. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.05.003 · Cited by 19
Mousapour, P., Barzin, M., Valizadeh, M., Mahdavi, M., Hadaegh, F., Azizi, F., & Hosseinpanah, F. (2021) · BMC Public Health · doi:10.1186/s12889-021-12371-7 · Cited by 19
“An extensive body of literature supports that MHO can be a transient condition, and approximately 30 to 50% of individuals with MHO have shown transition to metabolically unhealthy overweight/obese (MUO) phenotype during 4 to 20 years of follow-up [5].”
BackgroundResultWuni, R., Nathania, E. A., Ayyappa, K. A., Lakshmipriya, N., Ramya, K., Gayathri, R., Geetha, G., Anjana, R. M., Kuhnle, G., Radha, V., et al. (2022) · Nutrients · doi:10.3390/nu14132713 · Cited by 18
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010161 · Cited by 15
Diez-Roda, P., Perez-Navarro, E., & García-Martín, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413488 · Cited by 17
“4–35%, who do not display these abnormalities [145].”
Szalanczy, A., Chuang, C., & Woods, L. C. S. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108928 · Cited by 22
Cipryan, L., Dostal, T., Litschmannová, M., Hofmann, P., Maffetone, P. B., & Laursen, P. B. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.785694 · Cited by 18
“Being overfat can promote chronic low-grade systemic inflammation (4) which contributes to reduced life expectancy, impaired quality of life, and development of cardiovascular diseases, type 2 diabetes mellitus, osteoarthritis, cancer (5), hypertension (6) and nonalcoholic fatty liver disease (7).”
BackgroundReducing obesity and inflammation in mice with organically-derivatized polyoxovanadate clusters
Chen, K., Dai, G., Liu, S., & Wei, Y. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.06.061 · Cited by 15
Holwerda, S. W., Gangwish, M. E., Luehrs, R. E., Nuckols, V. R., Thyfault, J. P., Miles, J. M., & Pierce, G. L. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003335 · Cited by 17
“Indeed, subcutaneous abdominal obesity has been considered ‘metabolically healthy obesity’ characterized by normal glucose and lipid metabolism and the absence of hypertension [64].”
BackgroundPrecision nutrition for targeting pathophysiology of cardiometabolic phenotypes
Shannon, C. E., Chathail, M. B. N., Mullin, S. M., Meehan, A., McGillicuddy, F. C., & Roche, H. M. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09821-5 · Cited by 21
“However, the relationship between weight gain and metabolic decline is nonlinear, such that for any given body mass index (BMI) or body fat percentage there exists a continuum of cardiometabolic risk profiles [13].”
BackgroundMallik, R., Carpenter, J., & Zalin, A. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-0148 · Cited by 32
Yildirim, V., Sheraton, V. M., Brands, R., Crielaard, L., Quax, R., van Riel, N. A. W., Stronks, K., Nicolaou, M., & Sloot, P. M. A. (2023) · iScience · doi:10.1016/j.isci.2023.108324 · Cited by 19
Obesity – Standards, trends and advances
Gołacki, J., & Matyjaszek‐Matuszek, B. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.04.001 · Cited by 17
Czechowski, P., Hagemann, T., Ghosh, A., Sun, W., Dong, H., Noé, F., Niersmann, C., Reinisch, I., Wolfrum, C., Herder, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-72720-5 · Cited by 21
“Laboratory measurements of body composition and metabolic parameters had been obtained concomitantly 47,48 .”
Self-citationThe Close Link Between Obesity and Cardiovascular Disease
Lee, H., Rhee, T., Choi, J. M., Choi, S., & Kim, D. W. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.005 · Cited by 18
Serbis, A., Giapros, V., Paschou, S. Α., & Siomou, E. C. (2021) · Endocrine · doi:10.1007/s12020-021-02762-6 · Cited by 19
“The uncertainties that still exist regarding pediatric MHO definition may imply that MHO does not represent a biologically defined distinct subgroup of individuals with obesity and that it might not be a totally benign condition after all [16, 43].”
BackgroundVesikansa, A., Mehtälä, J., Mutanen, K., Lundqvist, A., Laatikainen, T. K., Ylisaukko‐oja, T., Saukkonen, T. T., & Pietiläinen, K. H. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01507-0 · Cited by 38
“However, there is large variation in individual risk of developing obesity-associated diseases, and the concept of metabolically healthy obesity (MHO) has been introduced to describe obesity in the absence of metabolic abnormalities [15].”
BackgroundThe silencing of miR-199a-5p protects the articular cartilage through MAPK4 in osteoarthritis
Lu, H., Yang, Y., Ou, S., Qi, Y., Li, G., He, H., Lu, F., Li, W., & Sun, H. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2057 · Cited by 15
Ghaffari, M. H., Sadri, H., & Sauerwein, H. (2022) · Journal of Dairy Science · doi:10.3168/jds.2022-22549 · Cited by 24
“About overconditioning in dairy cows, observa- tions made in human medicine that led to the notion of a metabolically healthy but obese phenotype are of particular interest: as reviewed by Blüher (2020), there is a subgroup of obese patients not showing the typical obesity-related morbidities.”
BackgroundSeo, M.-W., & Kim, J. Y. (2023) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2023.02.001 · Cited by 17
Liu, Y., Zhao, A., Sun, G., Wang, R., Zhang, J., Lip, G. Y. H., & Li, G. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01469-8 · Cited by 17
“Depending on some metabolic indicators that include blood pressure, lipid pro fi le and glucose tolerance, individuals with obesity can be described as metabolically healthy obesity (MHO) or metabolically unhealthy obesity (MUO) [3].”
Current prospects of metabolically healthy obesity
Ahmad, M. N., & Zawatia, A. A. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100361 · Cited by 17
Obesity phenotypes related to musculoskeletal disorders; a cross-sectional study from RaNCD cohort
Karimi, S., Pasdar, Y., Hamzeh, B., Ayenehpour, A., Heydarpour, F., & Goudarzi, F. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00947-7 · Cited by 22
Pathogenesis, Murine Models, and Clinical Implications of Metabolically Healthy Obesity
Cho, Y. K., Lee, Y. L., & Jung, C. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179614 · Cited by 16
“MHO is distinguished by the absence of metabolic disturbances, including insulin resistance, type 2 diabetes, hypertension, and dyslipidemia, commonly associated with a chronic inflammatory state [4,5].”
BackgroundElsabaawy, M., Torkey, M., Magdy, M., & Naguib, M. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-03151-9 · Cited by 14
“Hypertension and advancing age further amplify this risk, highlighting the necessity of early and comprehensive cardiometabolic screening in MASLD patients [19–21].”
Sparse System Identification of Leptin Dynamics in Women With Obesity
Amin, M. R., Pednekar, D. D., Azgomi, H. F., van Wietmarschen, H., Aschbacher, K., & Faghih, R. T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.769951 · Cited by 14
Hu, B., Chen, X., Chen, T., Xu, T., Cao, Y., Sun, J., Chen, X.-Y., Chen, S., & Chen, K. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103331 · Cited by 19
“Our findings indicated a significant association between ISS and the occurrence of adverse outcomes related to stroke, particularly mortality (eTable 8).”
Maio, G. D., Tafuri, M. G., Casillo, M., Messina, A., Allocca, S., Villano, I., Moscatelli, F., Monda, A., Marra, M. L., & Monda, V. (2026) · Nutrients · doi:10.3390/nu18061014 · Cited by 21
Falalyeyeva, T. M., Komisarenko, I., Yanchyshyn, A., Kovalchuk, O. I., Lozko, Y., Tsyryuk, O., Fagoonee, S., & Kobyliak, N. M. (2021) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.21.02766-x · Cited by 15
Zhu, X., Hu, J., Guo, H., Ji, D., Yuan, D., Li, M., Yan, T., Xue, C., Ma, H., Zhou, X., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s317739 · Cited by 16
Increased intestinal-fatty acid binding protein in obesity-associated type 2 diabetes mellitus
Tahapary, D. L., Fatya, A. I., Kurniawan, F., Marcella, C., Rinaldi, I., Tarigan, T. J. E., Harbuwono, D. S., Yunir, E., Soewondo, P., & Purnamasari, D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279915 · Cited by 18
“Metabolically healthy obesity and metabolically unhealthy obesity (MUO) differ in fat distribution, ectopic fat deposition, inflammatory markers, adipocyte dysfunction and insulin resistance [2].”
BackgroundEffects of Capsaicin on Glucose Uptake and Consumption in Hepatocytes
Zeng, H., Shi, N., Peng, W., Yang, Q., Ren, J., Hong, Y., Chen, L., Chen, Y., & Guo, J. (2023) · Molecules · doi:10.3390/molecules28135258 · Cited by 14
Hu, C., Wang, S., Lin, H., Wan, Q., Zheng, R., Zhu, Y., Li, M., Xu, Y., Xu, M., Zheng, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15525 · Cited by 19
Moreno, Ó., Reyes‐García, R., Pardo, I. M., López-Martínez, M., & Soler, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae039 · Cited by 15
Blood methylation pattern reflects epigenetic remodelling in adipose tissue after bariatric surgery
Müller, L., Hoffmann, A., Bernhart, S. H., Ghosh, A., Zhong, J., Hagemann, T., Sun, W., Dong, H., Noé, F., Wolfrum, C., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105242 · Cited by 17
“All laboratory analyses of metabolic parameters, anthropometric parameter and body composition were collected prior to both surgeries as detailed before 38,39 (Supp.”
MethodSelf-citationPalumbo, A. M., Jacob, C. M., Khademioore, S., Sakib, M. N., Yoshida‐Montezuma, Y., Christodoulakis, N., Yassa, P., Vanama, M. S., Gamra, S., Ho, P., et al. (2025) · Obesity Reviews · doi:10.1111/obr.13894 · Cited by 21
“160,161 The adiposity-based chronic disease (ABCD) framework also considers health and encompasses the amount, distribution, and function of adiposity as well as physical and cultural contexts that together, result in the development of adiposity-based complications and disease stages.”
Ding, Y., Zhang, T., Ma, H., Han, J. Z., Zhu, W., Zhao, X., Lu, X.-Y., Zhou, B., & Shi, X. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.4c12616 · Cited by 15
Lipedema: From Women’s Hormonal Changes to Nutritional Intervention
Tomada, I. (2025) · Endocrines · doi:10.3390/endocrines6020024 · Cited by 17
Discovery of different metabotypes in overconditioned dairy cows by means of machine learning
Ghaffari, M. H., Jahanbekam, A., Post, C., Sadri, H., Schuh, K., Koch, C., & Sauerwein, H. (2020) · Journal of Dairy Science · doi:10.3168/jds.2020-18661 · Cited by 14
Hamzeh, B., Pasdar, Y., Moradi, S., Darbandi, M., Rahmani, N., Shakiba, E., & Najafi, F. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02553-5 · Cited by 19
“In general, MHO phenotype should not be considered a safe condition that does not require treatment for obesity [15].”
BackgroundObesity Hinders the Protective Effect of Selenite Supplementation on Insulin Signaling
Hauffe, R., Rath, M., Agyapong, W., Jonas, W., Vogel, H., Schulz, T. J., Schwarz, M., Kipp, A. P., Blüher, M., & Kleinridders, A. (2022) · Antioxidants · doi:10.3390/antiox11050862 · Cited by 17
Self-citationMetabolically Healthy Obesity: Epidemiology, Criteria, and Implications in Chronic Kidney Disease
Cho, Y. K., & Jung, C. H. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22036 · Cited by 16
Zhang, W., Wang, W., Li, L., Miller, M. R., Cui, L., Liu, J., Wang, Y., Hu, D., Liu, S., Xu, J., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.159014 · Cited by 14
Ding, Y., Ge, T., Shen, J., Duan, M., Yuan, C., Zhu, Y., & Zhou, D. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01581-x · Cited by 14
“These individuals were classified as metabolically normal obesity (MNO), whereas the others as metabolically abnormal obesity (MAO) [5].”
BackgroundExploring obesity phenotypes: a longitudinal perspective
Rosero, R., Tamayo, M., Correa, R. R., Pantalone, K. M., Creel, D. B., Burguera, B. G., & Griebeler, M. L. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09976-3 · Cited by 16
Yang, M., Zhang, Y., Zhao, W., Ge, M., Sun, X., Zhang, G., & Dong, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1078331 · Cited by 20
“An important concept is metabolically healthy obesity, which refers to individuals with obesity who are free of other metabolic diseases (28).”
BackgroundIndividualised prescription of medications for treatment of obesity in adults
HOCKING, S. L., & Sumithran, P. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09808-2 · Cited by 16
“This ‘metabolically healthy obesity’ (MHO) has an estimated prevalence of 10 – 40% depending on the population studied and the definition used [19, 20].”
BackgroundZhang, X., Qi, Y., Zhang, Y., Deng, J., Chen, X., Li, R., Zhou, Q., & Fan, J. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2213770 · Cited by 18
“The most prevalent form of diabetes, type 2 diabetes (T2D), is one kind of complicated metabolic disorder marked by the combined occurrence of obesity, dyslipidemia, hypertension, hyperglycemia, and insulin resistance (Gao et al. 2018, 2019, Blüher 2020, Przezak, Bielka, and Pawlik 2022).”
Evidence for proton-pump inhibitor (PPI)-associated dysbiosis in metabolically unhealthy obesity
Burmeister, M. A., Smith, T. E., Fincher, T. K., & Weldon, A. J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1205490 · Cited by 16
“The genera Oscillospira and Clostridum, microbial sources of beneficial SCFAs, are more abundant in MHO individuals (9).”
BackgroundInfluentialZhao, L., & Qiu, X. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.013 · Cited by 13
Huang, J., Gao, T., Zhang, H., & Wang, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-43028-7 · Cited by 15
Hagemann, T., Czechowski, P., Ghosh, A., Sun, W., Dong, H., Noé, F., Wolfrum, C., Blüher, M., & Hoffmann, A. (2023) · Biomedicines · doi:10.3390/biomedicines11102806 · Cited by 14
Self-citationSahu, B., Sahu, M., Sahu, M., Yadav, M., Sahu, B., & Sahu, C. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301493 · Cited by 21
Retracted: Arterial Stiffness and Obesity as Predictors of Diabetes: Longitudinal Cohort Study
Cui, C., Wu, Z., Zheng, J., Chu, J., Zhu, J., Qi, Y., Zhang, Z., Wang, Z., Zhang, M., Mo, Z., et al. (2024) · JMIR Public Health and Surveillance · doi:10.2196/46088 · Cited by 14
RetractedLiao, J., Goodrich, J. A., Chen, W., Qiu, C., Chen, J. C., Costello, E. J., Alderete, T. L., Chatzi, L., Gilliland, F. D., & Chen, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-57751-2 · Cited by 13
“Although previous studies pointed out that populations with MHO could be protected from several obesity-related cardiometabolic disorders, such as cardiovascular diseases, diabetes or cancer 6,15,16 , other studies also reported that MHO was also associated with higher risk 7,17 .”
ResultJanota, O., Mantovani, M., Kwiendacz, H., Irlik, K., Bucci, T., Lam, S. H. M., Huang, B., Alam, U., Boriani, G., Hendel, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02420-x · Cited by 15
“It is known that there is a large variation in risk at an individual level to developing obe-sity-associated comorbid diseases and outcomes, which that cannot solely explained by the level of adiposity [28].”
BackgroundPescari, D., Mihuţa, M. S., Bena, A., & Stoian, D. (2024) · Nutrients · doi:10.3390/nu16193291 · Cited by 24
Ji, H., Zhu, X., Qiu, J., Zhang, S., Li, J., Liu, L., Li, X., & Muneeb, M. (2024) · Food & Function · doi:10.1039/d4fo04072d · Cited by 13
Hesperetin mitigates adipose tissue inflammation to improve obesity-associated metabolic health
Chen, Q., Chen, W., Zhang, B., Xue, L., Li, F., Zhang, L., Tong, H., & Zhu, Q. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114211 · Cited by 15
Investigating the Salivary Biomarker Profile in Obesity: A Systematic Review
Habobe, H. A., Pieters, R. H. H., & Bikker, F. J. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00618-y · Cited by 17
Precision Medicine for Obesity Treatment
Espinosa, M. A., Gutiérrez, R. D. J. R., Villamarin, J. L., & Acosta, A. J. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf102 · Cited by 17
Isidor, M. S., Dong, W., Servin-Uribe, R. I., Villarroel, J., Altıntaş, A., Ayala-Sumuano, J. T., Varela‐Echavarría, A., Barrès, R., Stephanopoulos, G. N., Macotela, Y., et al. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-01021-y · Cited by 14
“Interestingly, a proportion of subjects with obesity remain insulin sensitive, a condition known as “metabolically healthy obesity” [5, 6].”
BackgroundMilewska, E., Szczepanek‐Parulska, E., Marciniak, M., Krygier, A., Dobrowolska, A., & Ruchała, M. (2022) · Nutrients · doi:10.3390/nu14061307 · Cited by 13
Khadem, A., Shiraseb, F., Mirzababaei, A., Ghaffarian-Ensaf, R., & Mirzaei, K. (2022) · BMC Women s Health · doi:10.1186/s12905-022-01957-x · Cited by 14
“or hyperlipidemia, and lower prevalence of hypertension [8, 9].”
BackgroundWang, P., Liu, M., Zhuang, X., Guo, Y., Xiong, Z., He, L., Cai, X., Chen, Z., Peng, L., & Liao, X. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01288-3 · Cited by 14
“Such individuals are defined as having metabolically healthy obesity (MHO) and account for at least one-third of adults with obesity [5].”
BackgroundMarcus, Y., Segev, E., Shefer, G., Eilam, D., Shenkerman, G., Buch, A., Shenhar‐Tsarfaty, S., Zeltser, D., Shapira, I., Berliner, S. A., et al. (2023) · Biology · doi:10.3390/biology12050719 · Cited by 20
Montes‐de‐Oca‐García, A., Pérez‐Bey, A., Corral‐Pérez, J., Marín-Galindo, A., Calderón‐Domínguez, M., Velázquez‐Díaz, D., Casals, C., & Ponce‐González, J. G. (2023) · Nutrients · doi:10.3390/nu15112628 · Cited by 13
Editorial: Metabolically Healthy and Unhealthy Obese Children and Adolescents
Chiesa, C., Pacifico, L., Xi, B., & Cadenas‐Sánchez, C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.613703 · Cited by 15
“A growing interest has been raised regarding a subgroup of obese individuals, including children, who are metabolically healthy, for whom the term “metabolically healthy obese (MHO)” has been proposed (3, 4).”
BackgroundAdiposity and cancer: systematic review and meta-analysisPreprint
Watts, E. L., Gonzalez-Feliciano, A., Gunter, M. J., Chatterjee, N., & Moore, S. C. (2024) · medRxiv · doi:10.1101/2024.02.16.24302944 · Cited by 13
Jang, J., Ahn, M., Jeong, J., Lee, E. H., Kim, O.-H., Joo, S.-A., Baek, S. E., Maeng, H., Kim, Y. H., Hong, I., et al. (2025) · Theranostics · doi:10.7150/thno.116796 · Cited by 15
Clinical obesity in Asian people: bridging the gap between adiposity and disease
Lim, S.-A., Ji, L., Tham, K. W., Misra, A., & Kadowaki, T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01239-8 · Cited by 20
“These limitations contribute to misclassification of risk, especially in individuals with metabolically healthy obesity or who have metabolic obesity and a BMI within the normal range 36,37 .”
Abdominal fat quantification using convolutional networks
Schneider, D., Eggebrecht, T., Linder, A., Linder, N., Schaudinn, A., Blüher, M., Denecke, T., & Busse, H. (2023) · European Radiology · doi:10.1007/s00330-023-09865-w · Cited by 12
“…two readers for SAT and VAT quantification from an independent, previous assessment using a similar MRI protocol and semiautomated Matlab tool [8]. showed the superiority of the FCN models for SAT, and similar to higher performance for VAT as opposed to manual annotation alone or supervised…”
BackgroundMethodSelf-citationWeyman-Vela, Y., Guerrero‐Romero, F., & Simental‐Mendía, L. E. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02201-5 · Cited by 11
Chen, F., Shi, Y., Yu, M., Hu, Y., Li, T., Cheng, Y., Xu, T., & Liu, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-53229-3 · Cited by 17
“On the one hand, most people 20–40 40–60 ≥ 60 Gender Male Female Race Non-hispanic Non-hispanic were greatly ill before they dead, such as cancer, and caused great losses in weight, while people who were still in normal weight or overweight at the time of death might not suffer from disease,…”
BackgroundBertran, L., Capellades, J., Abelló, S., Aguilar, C., Auguet, T., & Richart, C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303569 · Cited by 13
Ma, W., Liu, Y., Wu, N., Zhang, H., Han, P., Wang, F., Wang, J., Xie, F., Niu, S., Hu, H., et al. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s302167 · Cited by 16
“tend to have a lower risk of all-cause or cardiovascular death than metabolically unhealthy people with obesity.(5,6) However, there are also opposing research results,(7) and the clinical significance of the metabolically healthy obese (MHO) group has not been extensively studied.”
BackgroundGhanemi, A., Yoshioka, M., & St‐Amand, J. (2021) · Medicines · doi:10.3390/medicines8100057 · Cited by 12
Metabolically healthy overweight/obesity and cancer risk: A representative cohort study in Taiwan
Lin, C.-J., Chang, Y., Hsu, H., Tsai, M.-C., Hsu, L., Hwang, L., Chien, K., & Yeh, T. (2021) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2021.10.004 · Cited by 12
Role of long non-coding RNAs in adipose tissue metabolism and associated pathologies
Corral, A., Alcalá, M., Durán-Ruiz, M. C., Arroba, A. I., Ponce‐González, J. G., Todorčević, M., Serra, D., Calderón‐Domínguez, M., & Herrero, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115305 · Cited by 14
“The former mechanism is less harmful as hypertrophy and ectopic fat lead to inflammation and disease development [34].”
BackgroundFrye, B. M., Register, T. C., Appt, S. E., Vitolins, M. Z., Uberseder, B., Chen, H., & Shively, C. A. (2023) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2023.106107 · Cited by 12
“Indeed, considerable variation exists in the occurrence of metabolic abnormalities across individuals considered obese (Blüher, 2020; Peeke and Chrousos, 1995).”
Wu, S., Song, L., Wang, L., Chen, S., Wu, M., Wang, Y., & Tian, Y. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17735 · Cited by 12
Assaf, S., Park, J., Chowdhry, N., Ganapuram, M., Mattathil, S., Alakeel, R., & Kelly, O. J. (2024) · Metabolites · doi:10.3390/metabo14070379 · Cited by 14
Tsuchiya, K., & Tsutsumi, T. (2025) · Biomolecules · doi:10.3390/biom15091278 · Cited by 12
Fatty Acid Profile and Desaturase Activity in Obesity: Roles, Mechanisms, and Clinical Relevance
Banaszak, M., Górna, I., & Drzymała-Czyż, S. (2025) · Metabolites · doi:10.3390/metabo15090595 · Cited by 12
Metadata
- Authors
- Blüher, M.
- Affiliations
- Helmholtz Munich (DE)
- Corresponding author
- Blüher, Matthias
- ORCID
- Blüher, Matthias
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-03-04
- Volume
- 41
- Issue
- 3
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7098708
- OpenAlex
- W3009496837
- Cited by
- 1,090
- References
- 123
- Citations by year
- 2026: 197 · 2025: 222 · 2024: 213 · 2023: 162 · 2022: 155 · 2021: 105 · 2020: 35
- FWCI
- 86.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (209933838)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- metabolically healthy obesity, obesity, cardiometabolic risk, type 2 diabetes, cardiovascular disease, insulin sensitivity, beta-cell function, ectopic fat, visceral fat, liver fat, leg fat, cardiorespiratory fitness, weight loss, obesity treatment, risk stratification
- MeSH terms
- Obesity, Metabolically Benign, Cardiometabolic Risk Factors, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.